C
Cartesian Therapeutics, Inc. (RNAC)
NGM – Real Time Price. Currency in USD
9.42
+0.49 (5.49%)
At close: Jun 26, 2026, 4:00 PM EDT
9.42
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:55 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
9.42
+0.49 (5.49%)
At close: Jun 26, 2026, 4:00 PM EDT
9.42
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:55 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $118.6M significantly exceed its total debt $11.9M, ensuring strong financial flexibility
Total current assets $122.0M exceed Total current liabilities $15.9M, highlighting excellent liquidity
Debt-to-equity ratio (-0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$22.2M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.65 | 6.05 | 10 | |
| Quick ratio | 7.65 | 5.63 | 10 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 0.04 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 6.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 111M | 26M | 39M | 3M | 2M |
| Gross Profit | 109M | 24M | 38M | -162K | -643K |
| Operating Income | 15M | -86M | -31M | -87M | -91M |
| Net Income | 35M | -257M | -77M | -130M | -152M |
| EBITDA | 17M | -85M | -29M | -84M | -89M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -39.71 | -275.57 | 1.0 |
| Next quarter | -60.25 | 34.01 | 5.5 |
| Current year | -80.35 | 17.31 | 5.0 |
| Next year | -16.5 | 7.84 | 3.5 |
| Weighted average score | 3.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -91.75 | 57.68 | 57.8 | -21.73 | 5.5 |
| Y/Y | -92.9 | -121.23 | -114.7 | 8.36 | 2.3 |
| 3y average | -39.88 | -275.17 | -237.48 | -54.16 | 1.0 |
| 5y average | 64.63 | -105.01 | -87.14 | -79.26 | 3.3 |
| Weighted average score | 3.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |